{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:42:43Z","timestamp":1781541763938,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences foundation of China","doi-asserted-by":"crossref","award":["81370668"],"award-info":[{"award-number":["81370668"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences foundation of China","doi-asserted-by":"crossref","award":["81470347"],"award-info":[{"award-number":["81470347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bbmt.2018.07.021","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:34:17Z","timestamp":1532046857000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Ran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.07.021_bib0001","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0005","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0007","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0008","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2016.04.014","article-title":"Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study","volume":"46","author":"Fang","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.leukres.2015.08.015","article-title":"Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: a single center experience","volume":"39","author":"Wu","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/bmt.2011.66","article-title":"Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis","volume":"47","author":"Hong","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0012","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2017.100","article-title":"Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia","volume":"52","author":"Zhang","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0013","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/leu.2014.186","article-title":"Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse","volume":"29","author":"Kohnke","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0016","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cll.2007.05.006","article-title":"Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia","volume":"27","author":"Wood","year":"2007","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0017","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","article-title":"Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia","volume":"116","author":"Buccisano","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0018","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.leu.2403627","article-title":"Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)","volume":"19","author":"Leroy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0019","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0021","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.bbmt.2015.06.014","article-title":"Interferon-alpha: a potentially effective treatment for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Mo","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2018.07.021_bib0022","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/17474086.2017.1326811","article-title":"Enhancing acute myeloid leukemia therapy- monitoring response using residual disease testing as a guide to therapeutic decision-making","volume":"10","author":"Tomlinson","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","article-title":"Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0024","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3324\/haematol.2009.010843","article-title":"Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia","volume":"95","author":"Elorza","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOH.0000000000000315","article-title":"Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?","volume":"24","author":"Buccisano","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0026","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0027","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","article-title":"The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia","volume":"20","author":"Buccisano","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2017.12.784","article-title":"Pre-transplant consolidation is not beneficial for adults with all undergoing myeloablative allogeneic transplantation","volume":"24","author":"Bejanyan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0029","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/bmt.2010.253","article-title":"TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies","volume":"46","author":"Inagaki","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0031","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2141.1999.01424.x","article-title":"A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation","volume":"105","author":"Murata","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0032","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3109\/10428194.2015.1102241","article-title":"The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission","volume":"57","author":"Zheng","year":"2016","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0033","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.leukres.2015.10.011","article-title":"Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory\/relapsed AML patients in NR status","volume":"39","author":"Liu","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0034","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bmt.2012.236","article-title":"Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0035","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.bbmt.2016.08.030","article-title":"Myeloablative versus reduced-intensity conditioning in patients with myeloid malignancies: a propensity score-matched analysis","volume":"22","author":"Sibai","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0036","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00277-013-1790-5","article-title":"Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia","volume":"92","author":"Krejci","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.07.021_bib0037","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbmt.2011.09.006","article-title":"Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen","volume":"18","author":"Saure","year":"2012","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118304105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:19Z","timestamp":1761059119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118304105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1083879118304105"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.021","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}